$326 Million is the total value of Decheng Capital LLC's 24 reported holdings in Q2 2024. The portfolio turnover from Q1 2024 to Q2 2024 was 45.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CG ONCOLOGY INC | $172,334,632 | -28.1% | 5,458,810 | 0.0% | 52.81% | +64.3% | ||
| NUVB | New | Nuvation Bio Inc. | $20,294,698 | – | 6,950,239 | +100.0% | 6.22% | – |
| RCUS | Arcus Biosciences, Inc | $13,246,902 | -19.3% | 869,790 | 0.0% | 4.06% | +84.4% | |
| ZNTL | Buy | Zentalis Pharmaceuticals Inc. | $12,558,107 | -62.0% | 3,070,442 | +46.2% | 3.85% | -13.3% |
| KRYS | KRYSTAL BIOTECH INC | $12,078,370 | +3.2% | 65,772 | 0.0% | 3.70% | +135.9% | |
| BYSI | BeyondSpring Inc. | $11,899,543 | -32.8% | 4,958,143 | 0.0% | 3.65% | +53.6% | |
| ILMN | Sell | Illumnia, Inc. | $11,353,099 | -35.9% | 108,767 | -15.7% | 3.48% | +46.4% |
| MRUS | Buy | MERUS NV | $10,597,229 | +131.2% | 179,098 | +75.9% | 3.25% | +428.1% |
| PHAT | PHATHOM PHARMACEUTICALS INC | $8,755,000 | -3.0% | 850,000 | 0.0% | 2.68% | +121.6% | |
| New | NEWAMSTERDAM PHARMA CO NV | $7,684,000 | – | 400,000 | +100.0% | 2.36% | – | |
| HLXA | MOONLAKE IMMUNOTHERAPEUTICS | $7,325,402 | -12.5% | 166,600 | 0.0% | 2.24% | +100.1% | |
| FDMT | 4D MOLECULAR THERAPEUTICS IN | $7,301,057 | -34.1% | 347,835 | 0.0% | 2.24% | +50.5% | |
| CRNX | CRINETICS PHARMACEUTICALS IN | $7,074,939 | -4.3% | 157,958 | 0.0% | 2.17% | +118.5% | |
| CYTK | CYTOKINETICS INC | $5,095,250 | -22.7% | 94,043 | 0.0% | 1.56% | +76.6% | |
| LEGN | Buy | LEGEND BIOTECH CORP-ADRadr | $4,365,134 | -9.9% | 98,558 | +14.1% | 1.34% | +105.8% |
| Aura Biosciences, Inc. | $3,897,596 | -3.7% | 515,555 | 0.0% | 1.19% | +119.9% | ||
| EQ | Equillium Inc. | $3,082,874 | -70.0% | 4,447,308 | 0.0% | 0.94% | -31.4% | |
| GeneDx Holdings Corp. | $2,708,206 | +186.3% | 103,604 | 0.0% | 0.83% | +553.5% | ||
| VERA | New | VERA THERAPEUTICS INC | $2,524,170 | – | 69,767 | +100.0% | 0.77% | – |
| Pyxis Oncology, Inc (formerly Apexigen) | $1,081,741 | -22.3% | 326,810 | 0.0% | 0.33% | +77.5% | ||
| ATRC | AtriCure Inc. | $610,168 | -25.1% | 26,797 | 0.0% | 0.19% | +71.6% | |
| New | GRAIL INC | $278,612 | – | 18,127 | +100.0% | 0.08% | – | |
| NUVBWS | New | Nuvation Bio Inc.warrants | $103,369 | – | 646,057 | +100.0% | 0.03% | – |
| New | ARCELLX INC | $64,959 | – | 1,177 | +100.0% | 0.02% | – | |
| Exit | Aadi Bioscience, Inc. | $0 | – | -526,329 | -100.0% | -0.16% | – | |
| Exit | Cue Health Inc. | $0 | – | -8,980,909 | -100.0% | -0.23% | – | |
| TXG | Exit | 10x Genomics, Inc. | $0 | – | -195,835 | -100.0% | -0.99% | – |
| ALPN | Exit | Alpine Immune Sciences, Inc. | $0 | – | -8,317,924 | -100.0% | -44.22% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2024-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Zentalis Pharmaceuticals Inc. | 3 | Q2 2024 | 8.9% |
| Arcus Biosciences, Inc | 3 | Q2 2024 | 4.6% |
| Illumnia, Inc. | 3 | Q2 2024 | 3.5% |
| KRYSTAL BIOTECH INC | 3 | Q2 2024 | 3.7% |
| BeyondSpring Inc. | 3 | Q2 2024 | 3.6% |
| PHATHOM PHARMACEUTICALS INC | 3 | Q2 2024 | 2.7% |
| Equillium Inc. | 3 | Q2 2024 | 1.4% |
| Aura Biosciences, Inc. | 3 | Q2 2024 | 1.3% |
| GeneDx Holdings Corp. | 3 | Q2 2024 | 0.8% |
| AtriCure Inc. | 3 | Q2 2024 | 0.5% |
View Decheng Capital LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-09-04 |
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-14 |
| 13F-HR | 2024-02-12 |
View Decheng Capital LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.